FRENCH REAL–LIFE OBSERVATIONAL STUDY “TOPASE” EVALUATING SAFETY AND EFFICACY OF PONATINIB CONFIRMS INDUCTION OF DEEP MOLECULAR RESPONSES IN 110 RESISTANT OR INTOLERANT CML PATIENTS
Résumé
Background: Ponatinib is a 3rd generation tyrosine kinase inhibitor (TKI) indicated in chronic phase (CP), accelerated phase (AP) and blast phase (BP) CML as well as in patients (pts) with T315I mutation. Aims: TOPASE is an observational cohort, designed to evaluate, with a 2 to 4 years follow-up period, the efficacy and safety of ponatinib in routine clinical practice. Methods: This interim analysis reports results from data of pts included in 42 CML French centers from February 2018 to December 2020.
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|